← All trials
NCT06980025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2025
- Primary completion
- Oct 31, 2028
- Completion date
- Feb 28, 2029
- First posted
- May 20, 2025
- Last posted
- Oct 31, 2025
- Enrollment
- 1800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- George Washington UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- Columbia UniversityOfficial
- Columbia UniversityCollaborator
- George Washington UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.